Ibuprofen/paracetamol - AFT Pharmaceuticals

Drug Profile

Ibuprofen/paracetamol - AFT Pharmaceuticals

Alternative Names: Acetaminophen/ibuprofen - AFT Pharmaceuticals; Acetaminophen/ibuprofen intravenous - AFT Pharmaceuticals; Acetaminophen/ibuprofen IV - AFT Pharmaceuticals; Maxigesic IV; Paracetamol/ibuprofen intravenous - AFT Pharmaceuticals

Latest Information Update: 05 Jan 2017

Price : $50

At a glance

  • Originator AFT Pharmaceuticals
  • Class Anti-inflammatories; Non-opioid analgesics; Phenylpropionates
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Postoperative pain

Most Recent Events

  • 29 Feb 2016 AFT Pharmaceuticals has patent protection for Ibuprofen/paracetamol IV FDC (AFT Pharmaceuticals website, February 2016)
  • 29 Feb 2016 AFT Pharmaceuticals plans a phase III trial for Postoperative pain in USA (NCT02689063)
  • 26 Nov 2015 AFT Pharmaceuticals and an undisclosed third party pharmaceutical company agree to co-develop ibuprofen/paracetamol for Postoperative pain before November 2015 (AFT Pharmaceuticals website, February 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top